Barclays lowered the firm’s price target on Iqvia (IQV) to $235 from $255 and keeps an Overweight rating on the shares. The firm says the life science tools group will likely continue to work overall on the last estimate cut thesis and Q1 guides “coming in very conservative” that makes it hard to see companies missing targets.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- Iqvia price target lowered to $210 from $212 at Baird
- Nvidia (NVDA) Expands Healthcare Presence with Illumina Partnership
- Iqvia announces strategic collaboration with Nvidia
- Iqvia working with Nvidia to build custom models, agentic AI workflows
- Nvidia enters partnerships in healthcare, life sciences industry